High prevalence of small intestinal bacterial overgrowth and intestinal methanogen overgrowth in endometriosis patients: A case-control study

Philippe Halfon, Halfon P, Jean‐Philippe Estrade, Estrade JP, Jean-Louis Estrade, Jean-Philippe Estrade, Guillaume Pénaranda, Choucroun N, Nathalie Choucroun, Jérôme Bouaziz, Bouaziz J, Alba Nicolás‐Boluda, Alba Nicolas-Boluda, Nicolas-Boluda A, Retornaz F, Frédérique Retornaz, F. Rétornaz, Gurriet B, Brice Gurriet, Anne Plauzolles
International Journal of Gynecology & Obstetrics · 2025 · vol. 170(1) , pp. 284–291 · doi:10.1002/ijgo.70005 · PMID:39959963 · W4407618504
article OA: closed CC0 ⤵ 2 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This case-control study found a significantly higher prevalence of small intestinal bacterial overgrowth and intestinal methanogen overgrowth in endometriosis patients compared to controls.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: The purpose of this study is to raise awareness of small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) prevalence among patients with endometriosis to improve global recommendations in the standard of care for endometriosis. METHODS: This case-control study included a cohort of 1027 women who underwent the lactulose breath test (LBT) during their healthcare check-up to diagnose SIBO and/or IMO from November 2021 to June 2023. One hundred and forty-eight endometriosis patients were selected based on magnetic resonance imaging or a histological assessment. Each were matched with an equal number of women without endometriosis based on the exact age. RESULTS: SIBO/IMO prevalence was significantly higher among women with endometriosis, with up to 136 out of 148 who tested positive, 91.9% (95% confidence interval [CI] 86.3-95.7%) against 123 in the control group, 83.1% [76.1-88.8%], P = 0.0223. Women with endometriosis showed a significantly higher incidence of altered transit than those without (85.8 vs. 71%, P = 0.0019) and an increased prevalence of constipation (67.8 vs. 44.7%, P = 0.0017) and dizziness (44.8 vs. 28.7%, P = 0.0245). Overall, methane overgrowth accounted for up to 63.2% in women with endometriosis who tested positive for methane overgrowth. SIBO H2 was associated with a higher risk of developing diarrhea (P = 0.0027), whereas those positive for IMO were at a higher risk of developing acid reflux (P = 0.0132). CONCLUSION: Abnormal digestive overgrowth should be assessed in all endometriosis cases, as this approach could offer a new therapeutic strategy.
Full text 2,014 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Abstract

Objective The purpose of this study is to raise awareness of small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) prevalence among patients with endometriosis to improve global recommendations in the standard of care for endometriosis.

Methods

This case–control study included a cohort of 1027 women who underwent the lactulose breath test (LBT) during their healthcare check-up to diagnose SIBO and/or IMO from November 2021 to June 2023. One hundred and forty-eight endometriosis patients were selected based on magnetic resonance imaging or a histological assessment. Each were matched with an equal number of women without endometriosis based on the exact age.

Results

SIBO/IMO prevalence was significantly higher among women with endometriosis, with up to 136 out of 148 who tested positive, 91.9% (95% confidence interval [CI] 86.3–95.7%) against 123 in the control group, 83.1% [76.1–88.8%], P = 0.0223. Women with endometriosis showed a significantly higher incidence of altered transit than those without (85.8 vs. 71%, P = 0.0019) and an increased prevalence of constipation (67.8 vs. 44.7%, P = 0.0017) and dizziness (44.8 vs. 28.7%, P = 0.0245). Overall, methane overgrowth accounted for up to 63.2% in women with endometriosis who tested positive for methane overgrowth. SIBO H2 was associated with a higher risk of developing diarrhea (P = 0.0027), whereas those positive for IMO were at a higher risk of developing acid reflux (P = 0.0132).

Conclusion

Abnormal digestive overgrowth should be assessed in all endometriosis cases, as this approach could offer a new therapeutic strategy. CONFLICT OF INTEREST STATEMENT The authors report no conflicts of interest. DATA AVAILABILITY STATEMENT All fully anonymized individual participant data that underlie the results reported in this article will be made available.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome Blind Loop Syndrome

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

Cited by (2)

Source provenance

europepmc
last seen: 2026-07-28T06:14:09.330459+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-07-28T06:10:47.718173+00:00
unpaywall
last seen: 2026-07-28T06:55:22.213180+00:00
License: CC0 · commercial use OK